Thursday, September 24, 2020
Home Life Style Health & Fitness Experimental Drug for Parkinson's Shows Progress

Experimental Drug for Parkinson’s Shows Progress

New drug for Parkinson's shows promise

An experimental drug has shown promise in treatment of debilitating movement problems in people with Parkinson’s disease. This is the latest health news.

The researchers investigated the effect of the drug NLX-112 on dyskinesia, a common side effect experienced by people with Parkinson’s who have been taking levodopa-based medications for several years. Levodopa is generally used as a dopamine replacement agent for the treatment of Parkinson’s.

The drug works by targeting serotonin cells inside the brain which are believed to contribute to the development of dyskinesia, by releasing dopamine in an erratic manner. It aims to reduce dyskinesia by decreasing the amount of dopamine the cells release, said the study published online in the journal Neuropharmacology.

The research was carried out by US-based biotech company Neurolixis with funding from Parkinson’s UK, a charity.

Parkinson's drug
The drug works by targeting serotonin cells inside the brain which are believed to contribute to the development of dyskinesia, by releasing dopamine in an erratic manner. (Representational Image). Pixabay

“This promising research on NLX-112 offers hope that we can find a treatment that can tackle dyskinesia, which can make everyday tasks, such as eating, writing and walking, extremely difficult,” said Arthur Roach, Director of Research at Parkinson’s UK.

“People with Parkinson’s tell us it is one of the most critical issues that impacts quality of life so we’re delighted that this project is progressing so positively,” Roach said.

Anyone can get Parkinson’s, young or old. Parkinson’s is what happens when the brain cells that make dopamine start to die. There are over 40 symptoms, from tremor and pain to anxiety. Some are treatable, but the drugs can have serious side effects. It gets worse over time and there’s no cure yet.

Around half of all people with Parkinson’s will experience dyskinesia after just five years of taking levodopa, and up to 80 per cent of people will experience it after ten years of taking the medication.

In this study, the drug NLX-112 was tested in monkeys with Parkinson’s-like symptoms. The monkeys had developed the side effect of dyskinesia in response to levodopa treatment in a similar way to many people with Parkinson’s.

The study looked at the effect of NLX-112 both on its own and in combination with levodopa, to understand how it impacted both dyskinesia and Parkinson’s symptoms.

The results showed that NLX-112 successfully reduced dyskinesia and crucially, did not significantly reduce the effectiveness of levodopa, which many other similar drugs do.

Also Read- 2 Experimental Drugs Fail to Prevent Alzheimer’s Disease

When NLX-112 was used on its own (without levodopa), it again improved movement problems.

These promising results suggest that NLX-112 has potential as a future treatment for not only reducing dyskinesia, but also for improving the movement symptoms of Parkinson’s, said the study. (IANS)

STAY CONNECTED

19,143FansLike
362FollowersFollow
1,774FollowersFollow

Most Popular

Microsoft Study Shows Pandemic has Increased Feeling of Burnout Among Workers

If you've been feeling overwhelmed at work lately, you are not alone as a new Microsoft study has shown that the pandemic has increased...

Lower Zinc Levels in Blood Linked to Higher Death Risk in Covid Patients: Study

In a major study, researchers have found that having a lower level of zinc in the blood is associated with a poorer outcome in...

Time Magazine List of 100 Most Influential People: Ayushmann Khurrana Among 5 Indians

Indian actor Ayushmann Khurrana is in the Time magazine list of 100 Most Influential People this year. Follow NewsGram on LinkedIn to know what's happening...

Return to Usual Sexual Activity After Heart Attack for Long-Term Survival

Returning to usual levels of sexual activity within a few months after a heart attack is positively associated with long-term survival, say researchers. According to...

Researchers Find Potential New Drug Candidate Against Enterovirus

Some good news in the search for antiviral drugs for hard-to-treat diseases as researchers have identified a potential new drug candidate against enterovirus 71,...

Stroke Patients With Covid-19 Show Increased Inflammation, Death Rate: Researchers

Stroke patients who also have Covid-19 showed increased systemic inflammation, more serious stroke severity and a much higher rate of death, compared to stroke...

Playing Video Games in Childhood Can Improve Working Memory Years Later

In a good news to video game lovers, researchers have found that playing video games as a child can improve working memory years later. The...

Know the Negative Impact of Covid-19 Lockdown on Kids

Children, who appear at a relatively lower risk from Covid-19, are disproportionately harmed by precautions involved with lockdowns, warn researchers. Experts from Oxford University Hospitals...

Recent Comments